The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in AdultsShow others and affiliations
2021 (English)In: Advances in Therapy, ISSN 0741-238X, E-ISSN 1865-8652, Vol. 38, no 5, p. 2054-2076Article, review/survey (Refereed) Published
Abstract [en]
Chronic diarrhea is a frequent presenting symptom, both in primary care medicine and in specialized gastroenterology units. It is estimated that more than 5% of the global population suffers from chronic diarrhea. and that about 40% of these subjects are older than 60 years. The clinician is frequently faced with the need to decide which is the best therapeutic approach for these patients. While the origin of chronic diarrhea is diverse, impairment of intestinal barrier function, dysbiosis. and mucosal micro-inflammation are being increasingly recognized as underlying phenomena characterizing a variety of chronic diarrheal diseases. In addition to current pharmacological therapies, there is growing interest in alternative products such as mucoprotectants, which form a mucoadhesive film over the epithelium to reduce and protect against the development of altered intestinal permeability, dysbiosis, and mucosal micro-inflammation. This manuscript focuses on chronic diarrhea in adults, and we will review recent evidence on the ability of these natural compounds to improve symptoms associated with chronic diarrhea and to exert protective effects for the intestinal barrier.
Place, publisher, year, edition, pages
Springer, 2021. Vol. 38, no 5, p. 2054-2076
Keywords [en]
Adults, Bismuth subsalicylate, Chronic diarrhea, Gelatine tannate, Mucoprotectans, Mucus, Smectite intestinal permeability, Xyloglugan
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-101131DOI: 10.1007/s12325-021-01676-zISI: 000630279500001PubMedID: 33738725Scopus ID: 2-s2.0-85103058775OAI: oai:DiVA.org:oru-101131DiVA, id: diva2:1693830
Funder
Swedish Research CouncilEuropean Commission
Note
Funding Agencies:
Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigacion Sanitaria and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Subdireccion General de Investigacion Sanitaria, M
Ajuts per a la contractacio de personal investigador FI-Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR)
Generalitat de Catalunya
CIBERehd
2022-09-082022-09-082022-09-08Bibliographically approved